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Resumo 
 
 
A síntese proteica é um processo essencial para que todos os 
organismos mantenham a homeostasia celular. Os tRNAs são 
elementos cruciais na síntese proteica, uma vez que codificam a 
informação genética presente no mRNA.  
A linha celular HeLa, utilizada neste estudo, foi primeiramente 
isolada de uma mulher com cancro do colo do útero e desde então 
tem sido bastante usada na investigação, sendo muito importante 
no estudo das bases moleculares de muitas doenças.  
De modo a monitorizar a agregação proteica nesta linha 
celular, um sistema repórter foi desenvolvido utilizando uma fusão 
entre HspB1 (Hsp27) e a GFP. HspB1 é um chaperone molecular 
com capacidade de recrutar outros chaperones e restabelecer a 
conformação ideal das proteínas em situações de stress. A GFP é 
uma proteína fluorescente que marca certas condições biológicas
de interesse.  
Para perceber o impacto dos erros da tradução na agregação 
de proteínas e no surgimento das doenças, o principal objetivo 
deste estudo foi desenvolver uma linha celular estável (HeLa) 
expressando um sistema repórter HspB1-GFP, de modo a 
monitorizar os erros no enovelamento das proteínas em resposta
ao stress proteotóxico. Ao longo deste estudo o sistema repórter 
expressando HspB1-GFP foi desenvolvido com sucesso, 
permitindo assim a sua utilização para identificar situações 
fisiológicas e patológicas em que a agregação de proteínas ocorre 
em células de mamífero. 
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Abstract 
 
Protein synthesis is essential for all organisms to maintain cell 
homeostasis. tRNAs are crucial elements in protein synthesis as 
they decode the genetic information organized in the mRNA 
codons.  
A HeLa cell line, used in this study, was first isolated from a 
woman with cervical cancer and since then was highly used in 
biological studies, being extremely important in the study of the 
molecular basis of several diseases. 
In order to monitor protein aggregation in this cell line, a 
reporter system was developed using an HspB1 (Hsp27) and a 
GFP fusion. HspB1 is a small heat shock protein that, in stress 
situations, recruits other proteins in order to restore the 
conformation of the proteins. GFP is a biosensor that reports 
several cellular conditions of interest. 
To understand the impact of translation errors on protein 
aggregation and on the disease arising, the main goal of this study 
was to develop a stable cell line (HeLa) expressing a reporter 
system HspB1-GFP to monitor the protein misfolding in response 
to proteotoxic stress. During this study, the reporter system 
expressing HspB1-GFP was developed successfully, allowing the 
identification of physiological and pathological situations where 
protein aggregation occurs in mammalian cells. 
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1.1. Genetic Code 
Although Francis Crick believed that the genetic code is universal for all species, as 
he presented in 1968 (1), some deviations to the code have been identified in some 
organisms, mainly in organelles. However the molecular basis of the genetic code remains 
basically the same in all organisms (2). 
The genetic code comprises 64 possible three-nucleotide combinations (codons) 
between the four nucleotides present in the messenger RNA (mRNA), namely, adenosine 
(A), cytosine (C), guanine (G) and uridine (U). A and G are purines and C and U are 
pyrimidines (3). However, only 20 amino acids are coded, which indicates the 
degenerative character of the genetic code. Thus, some amino acids have more than one 
codon that decodes them and these codons are regularly called synonymous codons (3-5). 
However, there is only one specific codon that decodes a specific amino acid to initiate the 
translation mechanism, which is the start codon methionine (AUG) and three specific stop 
codons (UAA, UAG, UGA) that do not decode any amino acid (2) (Figure 1). 
 
 
 
 
 
 
Figure 1. Genetic code. Adapted from Clancy, S. and Brown, W. 2008. 
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1.2. Eukaryotic Translation 
 Proteins are involved in all cellular functions, from metabolism and cellular 
division, to cellular response to environmental stimuli. Thus, maintaining a stable 
proteome is essential for cell survival (6, 7). 
Proteins are the final products of gene expression. This important mechanism that 
takes place in the cell has two important steps, transcription and translation. In the 
transcription process, which occurs in the cell nucleus, the information contained in DNA 
is transferred to a mRNA molecule. This molecule is, later, converted into a protein, in a 
process called translation or protein synthesis. This process takes place in ribosomes that 
are ribonucleoproteins located in the cytoplasm of the cells, containing a small and a large 
subunit, respectively 40S and 60S, according to the sedimentation velocity. These two 
subunits contain ribosomal RNA (rRNA), transfer RNA (tRNA) and proteins. In the 
presence of mRNA0 transcripts the small and large subunits join to each other and a tRNA 
molecule containing a sequence of nucleotide triplets that is complementary to the mRNA, 
called the anticodon, can pair with the codon. The rRNA facilitates the attachment of a 
new amino acid to the chain in formation (8). 
The ribosome has three sites for tRNA binding, the A-site, P-site and E-site. The 
aminoacyl-tRNAs are first recruited to the A (amino acid) site where they can base pair 
with the mRNA codon. The amino acid is transferred from its tRNA to the polypeptide 
chain in formation on the P (polypeptide) site. The E (exit) site is where binds a free tRNA 
before being released to the cytoplasm (9).  
 Translation can be divided in four steps: initiation, elongation, termination and 
recycling that will be described below (Figure 2).  
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Figure 2. mRNA translation in eukaryotes. a) Initiation. Translation begins with a formation of a 43S pre-
initiation complex constituted by the 40S ribosome subunit, eIF1, eIF3 complex, eIF5 and the tRNAMet. This 
complex binds to the mRNA, promoting the scanning along the mRNA for the AUG codon. Once founded 
the start codon, the large ribosomal subunit links to the initiation complex and the next phase can occur. b) 
Elongation. The charged tRNAs are delivered to the A-site of the ribosome and a peptide bond is formed 
between the methionine and the second amino acid. The ribosome then translocates to the next codon and the 
polypeptide chain is formed according to the mRNA sequence. c) Termination. A stop codon is detected, 
triggering the release of the mRNA, ribosome dissociation and recycling of the translation components. 
Adapted from Walsh, D. and Mohr, I. 2011. 
 
1.2.1 Initiation  
The initiation of the translation of the mRNA requires the presence of initiation 
factors (IFs), which bind to the small subunit of the ribosome (10). Translation begins with 
the formation of a ternary complex that includes eIF2, guanosine triphosphate (GTP) and 
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methionine-carrying tRNA. Then, the ternary complex binds to the small subunit of the 
ribosome, which is catalyzed by IF1, IF1A and IF3. The 5’ mRNA CAP is recognized and 
assembled by the eIF4F complex that unfolds structures in the 5’ untranslated region 
(UTR). The eIF4F complex with eIF3 and poly(A) binding protein (PABP) link to the 3’ 
poly(A) tail and bind the mRNA to the ternary complex recently formed, now called 43S 
complex, allowing the scanning of the mRNA in the 5’ to 3’direction (10). When the start 
codon (AUG) is found, the base pairing between the anticodon of tRNAMet and the initiator 
codon of the mRNA can occur in the P-site of the small subunit. GTP is hydrolyzed by 
eIF2 and GTPase-activating protein (GAP) eIF5 and then, eIF2-GDP and other factors, are 
released from the complex. Once the initiation complex containing the 40S subunit, the 
mRNA chain and the initiator aminoacyl-tRNA is formed, the large subunit (60S) of the 
ribosome can link to it, leading to the GTP hydrolysis by eIF5B. Then, the eIF5B-GDP 
dissociates from the complex, leading to the end of initiation (11-14).  
 
1.2.2.  Elongation 
In the beginning of elongation the tRNAMet is in the P-site and the A-site is empty. 
Then, the aminoacyl-tRNA that corresponds to the second codon of the mRNA, either the 
cognate or noncognate is carried out to the A-site, creating a ternary complex with a GTP 
and eEF1A (12). Conformational changes on the decoding center of the 40S subunit of the 
ribosome, hydrolysis of GTP by eEF1A and codon-anticodon interactions ensure the 
cognate tRNA presence. The eEF1A-GTPase complex is activated, leading to the release 
of the aminoacyl-tRNA into de A-site by eEF1A-GDP. The resulting eEF1A-GDP must be 
recycled by eEF1B complex (eEF1Bα and eEF1Bβ) to GTP to be reused in several cycles 
of polypeptide elongation (8, 11). 
The peptidyl transferase center in the large ribosomal subunit, then, catalyzes a 
peptide bond formation between methionine and the recently added amino acid. The 
resulting hybrid deacylated tRNA occupies the P-site of the small subunit and its acceptor 
end is in the E-site of the large subunit of the ribosome. Still, the peptidyl-tRNA has its 
anticodon end in the A-site of the small ribosomal subunit and its acceptor in the P-site of 
the large subunit. The next step, catalyzed by eEF2 and GTP, is translocation, where the 
deacylated tRNA moves to the E-site of the large subunit of the ribosome and the peptidyl-
tRNA moves to the P-site. At the same time the mRNA moves three nucleotides towards 
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the 3’ end to put a new codon into the A-site to be decoded. This process is repeated until 
the detection of a stop codon and the elongation process ends, giving place to the next 
phase of the translation mechanism (8, 11, 12). 
 
1.2.3. Termination 
The termination process occurs when the A-site of the ribosome encounters a stop 
codon. There are three termination codons: UAA, UAG and UGA that none of the tRNAs 
recognize (15). Thus, some proteins, namely eukaryotic release factors (eRF) class 1 and 2, 
decode these stop codons presented in the A-site of the ribosome. eRF2 are GTPases that 
stimulate the activity of eRF1, which promotes the release of the mRNA from the 
ribosome and its dissociation with the hydrolysis of the ester bound between the 
polypeptide chain and the P-site where the tRNA is. So, the components of the elongation 
complex dissociate, forming separated subunits. The peptidyl transferase center may play a 
role in this hydrolysis reaction too (8, 11). 
 
1.2.4. Recycling 
The last stage of translation is the recycling of the translation components to be 
further used in another translation cycle. There is lack of information about this mechanism 
and how this acts in eukaryotic cells. However, the mRNA, the deacylated tRNA and the 
ribosomal subunits have to be separated and recycled to initiate another translation process 
(11, 15). 
There is a model that suggests that termination and recycling partially dissociate 
ribosome subunits, in a process called reinitiation of translation. This mechanism results in 
the shuttle of the 40S subunit across the poly(A) tail to the 5’ UTR of the mRNA (15). 
Some findings suggest that eRF3 and PABP interact to each other to link termination 
apparatus to the poly (A) tail, being this interaction important for termination and recycling 
process. However, these findings are still unproven (11). 
eIF3 may also have an important role in the recycling process in eukaryotes. Some 
studies refer that this factor binds to the small subunit of the ribosome and promotes 
conformational changes, preventing the binding of the large ribosomal subunit, and 
consequently, promoting the dissociation between these two subunits (11). 
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1.3. Transfer RNA 
tRNAs are adaptor molecules that participate in the translation process. They 
transport amino acids to the ribosome to decode a mRNA sequence, producing functional 
proteins (16-19). These RNA molecules, discovered by Paul Zamecnik and collaborators, 
are the most abundant, representing up to 10% of all RNAs (16, 19). They play an essential 
role in protein biosynthesis and are able to evaluate the availability in amino acids; 
however tRNAs participate in several other activities, such as biosynthesis of some 
metabolites, degradation of proteins, apoptosis and production of tRNA-derived fragments, 
a type of small interfering RNAs. Their uncharged form has a role in signal transduction 
pathways in response to nutrient deficiency (16, 20, 21). 
 tRNAs are composed by 73 to 93 nucleotides with a 3’CCA end in the mature form 
that is highly conserved among species. tRNAs fold into a cloverleaf in their secondary 
structure and acquire a L-shaped three dimensional conformation in their tertiary structure 
(18, 19). The secondary structure is composed by an acceptor arm, a D arm, an anticodon 
arm and a TΨC arm, which has a variable arm between it and the anticodon arm (Figure 3) 
(17, 22).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. tRNA cloverleaf secondary structure. Adapted from Torres, AG, et al. (2014). 
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The L-shaped tertiary structure is generally conserved and found in almost all 
tRNA species, providing information about movements in the ribosome throughout 
translation. The tertiary structure is formed by the stacking between the acceptor and the 
TΨC arms and between the D arm and the anticodon arm.  The D and TΨC loops join 
together to form the L-shape (16, 17, 19). 
After maturation, each tRNA is charged with a cognate amino acid linked to the 
adenosine in the 3’CCA tail and the mRNA codon base-pairs with the anticodon, reading 
three nucleotides at a time, at the anticodon loop (17).  
tRNA genes are transcribed by RNA polymerase III and to be fully active they have 
to go through some processes, which includes the removal of extra sequence at the 5’ 
terminus by endonuclease RNase P and the cleavage of the 3’ end sequence by 
endonuclease RNase Z and exonucleases.  Then, the post-transcriptional addition of CCA 
sequence on the 3’ end by Transfer RNA nucleotidyltransferases using ATP as substrate. 
And finally, splicing of introns and post-transcriptional modification of some nucleotides 
(16, 20). 
 The mRNA codon is presented to the three bases of the anticodon at positions 34, 
35, 36. Watson and Crick in 1966 established that interactions between the first and second 
positions of the mRNA codon and tRNA anticodon are made according to base-pairing 
rules that G pairs with C and A pairs with U (23). However, at the third position of the 
mRNA, the nucleotide can perfectly pair with anticodon or pair with other nucleotides 
present in the position 34 of the tRNA anticodon, allowing the tRNA to recognize different 
codons coding for the same amino acid. For example, inosine, which is formed by 
deamination of A can pair with A, C or U at position 34 of the anticodon, allowing to this 
wobble hypothesis development. Modifications at position 37 of tRNA stabilize 
interactions between codon and anticodon, preventing translational frameshift (23, 24). 
 
1.3.1.  tRNA Aminoacylation 
tRNA aminoacylation reaction is catalyzed by a group of at least 20 enzymes, the 
aminoacyl-tRNA synthetases (aaRSs). These ubiquitous enzymes control the fidelity of 
protein synthesis through the attachment of amino acid to their cognate tRNA (25). aaRS 
have a variety of functions, including transcriptional and translational control, apoptosis 
inhibition, stimulation of immune system and angiogenic signaling (25, 26). 
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The aminoacylation reaction occurs in two major steps (Figure 4). In the first step, 
the cognate amino acid binds to the aaRS, in a process dependent of ATP, leading to the 
formation of an aminoacyl adenylate (aa-AMP) and releasing of a pyrophosphate (PPi) 
molecule. In the next step, a tRNA molecule binds to the aaRS complex and the amino acid 
is transferred to the tRNA, leading to the release of the AMP molecule, the tRNA charged 
with the cognate amino acid and the aaRS that is now able to start a new aminoacylation 
reaction (26, 27). 
 
aa + ATP + aaRS               (aa-AMP)aaRS + PPi 
(aa-AMP)aaRS + tRNA                aa-tRNA + AMP + aaRS 
Figure 4. Representation of the aminoacylation reaction. aa, amino acid; aaRS, aminoacyl-tRNA synthetase; 
PPi, pyrophosphate; AMP, adenosine monophosphate. Tamura, K. 2009. 
 
tRNAs can be charged in three different places of the cell, in the nucleus, cytoplasm 
and in the mitochondria, where translation occurs. Thus, aaRSs have to be in these cell 
regions, and to promote this process, nuclear aaRSs are imported to the mitochondria. So, 
each aaRS can be classified according their localization to charged tRNAs. In humans, 16 
aaRS are present in the cytoplasm, where they act, 17 in the mitochondria and 3 are 
bifunctional, which are able to charge tRNAs in both places (26). aaRS can also be 
classified into two groups, according to their structural features. Group I have active sites 
with the Rossman fold (parallel β-sheet nucleotide-binding), whereas group II have 
antiparallel β-sheets with three motifs in their active sites (19, 26). 
To avoid errors in tRNA charging that can affect protein synthesis fidelity, aaRSs 
have an editing ability, removing incorrect amino acids from tRNAs before they reach the 
ribosome. This quality control mechanism takes place at the aminoacylation step, in the 
active site, which differentiate non-cognate from cognate amino acids (28). Editing process 
can occur before or after the non-cognate amino acid is attached to the tRNA, in a 
pretransfer editing mechanism or a posttransfer editing, respectively. In pre-transfer editing 
mechanism, the amino acid incorrectly activated is hydrolyzed before its transference to 
the 3’ end of the tRNA, either by translocation, release or hydrolysis of the active site;  
whereas post-transfer editing needs the translocation of the 3’ end of the mischarged tRNA 
between the active site and the editing site (29). 
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Despite these editing mechanisms to control protein synthesis fidelity, mutations in 
some aaRSs genes can occur and are responsible for the appearing of several diseases, 
mostly neurodegenerative disorders, characterized by accumulation of misfolded proteins 
and protein quality control systems saturation (26, 30). 
 
1.3.2. tRNA Modifications 
There are more than 600 different sequences of tRNA known so far, with about 120 
modified nucleosides, mostly at the anticodon loop, and more than 100 of enzymes 
required to catalyze these modifications at the post-transcriptional level. Many studies refer 
that heavily modified tRNAs are more stable than unmodified ones (16, 20, 31).  
Modifications at position 34 of tRNAs are more associated with decoding, whereas 
modifications at position 37 of tRNA stabilize interactions between codon and anticodon 
(24). Modifications at the wobble position are essential for recognition of rare codons. The 
absence of these modifications, either at the wobble position or at position 37 of tRNA 
anticodon, promotes translational frameshift and increase levels of missense errors, 
compromising protein synthesis (32). Some evidences refer that defects on these 
modifications or in enzymes that catalyze these modifications can trigger the accumulation 
of misfolded proteins, leading to protein aggregation and to the appearing of some 
disorders, such as neurodegenerative diseases, cancer and mitochondrial related diseases 
(33-37) . Therefore these modifications are crucial for translation efficiency as well as 
tRNA stability, being catalyzed by different groups of tRNA modifying enzymes (Table I) 
(24). 
 
Table I. Examples of human tRNA modifying enzymes and respective modifications as well as the associated 
diseases. Adapted from Torres, AG, Batlle E and Ribas de Pouplana, L (2014). 
tRNA modifying enzymes Modifications Diseases 
tRNA methyltransferase 1 
(TRM1) 
N2,N2-dimethyl guanosines (m22G) 
at position 26 
Cognitive disorders 
FtsJ RNA methyltransferase 
homolog 1 (FTSJ1) 
2’O-methylribose at positions 32 and 
34  
Intellectual disability 
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NOP2/Sun RNA 
methyltransferase family 
member 2 (NSUN2) 
5-methylcytosine (m5C) at positions 
34, 48, 49 and 50 
Intellectual disorders, 
mental retardation 
and cancer 
Adenosine deaminase acting on 
tRNA 3 (ADAT3) 
Conversion of adenosine-to-inosine 
(A-to-I editing) at position 34 
Intellectual disability 
Elongator Protein 3 homolog 
(ELP3) 
5-methoxycarbonylmethyluridine 
(mcm5U) and 5-
methoxycarbonylmethyl-2-
thiouridine (mcm5s2U) at position 34 
Amyotrophic Lateral 
Sclerosis (ALS) 
Elongator Protein 4 homolog 
(ELP4) 
5-methoxycarbonylmethyluridine 
(mcm5U) and 5-
methoxycarbonylmethyl-2-
thiouridine (mcm5s2U) at position 34 
Epilepsy 
tRNA methyltransferase 12 
(TRMT12) 
Wybutosine at position 37 Breast cancer 
DNA methyltransferase 2 
(DNMT2) 
5-methylcytosine (m5C) at position 
38 
Epigenetic cancer 
therapy 
Mitochondrial (mt) 
tRNALeu(UAA) 
5-taurinomethyluridine (tm5U) 
Mitochondrial 
myopathy, 
encephalopathy, 
lactic acidosis, and 
stroke-like episodes 
(MELAS) 
Mitochondrial (mt) 
tRNALys(UUU) 
5-taurinomethyl-2-thiouridine 
(tm5s2U) 
Myoclonus epilepsy 
associated with 
ragged-red fibers 
(MERRF) 
 
1.4. Protein Folding  
Maintaining a stable proteome is essential for cell survival, since proteins are 
involved in every cellular mechanisms (7). Thus, to function properly, proteins need to fold 
into its native three dimensional structures, which are characteristic of each protein and 
involve the action of weak non-covalent bonds between amino acids (38, 39). The 
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sequences of amino acids have all the information necessary to proper folding, which 
depends on the amino acid sequence characteristics and on the cellular milieu. In this 
process several molecular chaperones and proteases participate, to ensure the quality of the 
final product (40). Although the number of different protein conformations is very large, 
the protein must acquire the conformation with the lowest energy, despite the native state 
of some proteins is not necessarily the lowest-energy form. Moreover, correctly folded 
proteins have stability for long time and can interact with other biological structures in cell 
environments (41). 
In the past years significant efforts were made to understand the process of folding 
(Figure 5). Some studies refer that, beyond the unfold and the native states, the nascent 
polypeptide chain, after translation, can also acquire an intermediary compact structure, 
named molten globule, which is an intermediate configuration. Thus, the protein folding 
process can be divided in three major steps: fast secondary structures formation, formation 
of the molten globule and formation of the native protein. The formation of this structures 
depends on the hydrophobic groups and the heterogeneity of the stabilizing interactions 
and the native structures are obtained through the hydrogen bonds, van der waals and 
electrostatic interactions (38, 42). 
 
Figure 5. Representation of the folding process. Adapted from Naeen A, Khan TA, et al. 2015 
 
The mechanism of folding is initiated, in some cases, after protein translation, when 
the recently formed chain is still attached to the ribosome. In other cases, protein folding 
occurs in the cytoplasm of the cell, after ribosome release. And finally, proteins can either 
fold in specific compartments, such as endoplasmic reticulum (ER) or in the mitochondria. 
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Although the folding process depends on the environment in which it occurs, the basic 
mechanisms are still the same (43). 
Protein folding forms a large variety of structures that are in tight relation with 
other important functional groups, promoting the different systems to develop diversity in 
their chemical mechanisms. Also the folding process is associated with other biological 
processes, such as, the trafficking of molecules to specific cell compartments, regulation of 
cell growth, as well as differentiation (43). 
The existence of polypeptide chain errors, from gene variations or deficient amino 
acid modifications, can modify protein folding, resulting in the formation of misfolded 
proteins and deregulation of protein homeostasis. Accumulation of misfolded proteins and 
alteration of protein homeostasis are in the basis of the appearance of several diseases, 
from cancer to neurodegenerative disorders. However, the cell has protein quality controls 
that are activated to maintain the stability of the proteins, in response to environmental or 
physiological stress (44, 45). 
 
1.5. Protein Quality Control  
A stable proteome is essential for cell stability and survival, because proteins are 
crucial substances that ensure cell homeostasis. For that, the cell has highly regulated 
vigilance systems that ensure that proteins are correctly translated and folded, avoiding 
aggregation and eliminating misfolded and damaged proteins. When cell homeostasis is 
changed, mostly derived from stress situations, protein quality control systems are 
activated (6, 7, 44). The protein quality control (PQC) system is constituted by molecular 
chaperones, intracellular proteases and accessory factors that assist in the folding of the 
different proteins (44). 
Proteins are translocated into the ER, where they acquire their three-dimensional 
conformation and become functional, before its secretion through the Golgi apparatus. The 
lumen of the ER is composed by highly concentrations of chaperones and folding enzymes. 
In this way, the PQC systems need to satisfy a set of characteristics to distinguish folded 
from misfolded proteins and to avoid the releasing of aberrant proteins into the 
extracellular environment to exert their function (43, 44). Accumulation of misfolded 
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proteins is detected by the PQC systems that send these incorrectly folded proteins to 
refold by molecular chaperones and other folding proteins or, if it is not possible, to 
degradation by endoplasmic reticulum associated degradation (ERAD) or autophagy (43, 
46). 
Although the PQC is very important for cell homeostasis maintenance, protein 
folding and the removal of proteins with aberrant conformation, the existence of errors can 
interfere with these systems and lead to the appearance of several diseases (44). Aging 
itself can be another stressing agent that promotes the loss of efficiency of PQC, leading to 
protein homeostasis imbalance, protein aggregation and disease (7, 44). 
 
1.5.1. Molecular Chaperones 
The molecular chaperones are proteins that assist in de novo folding or refolding of 
misfolded proteins. This protein family plays essential roles in protein folding, through the 
maintenance of the protein complexes in folding competent state, target unfolded or 
misfolded proteins, translocation across cellular compartments, and direct misfolded 
proteins to degradation by the proteasome and also have a role in signal transduction (7, 
47, 48).  
The majority of the members of the chaperones family are designated by heat shock 
proteins (HSPs), as they are upregulated with the high temperatures and other stress 
conditions (49). HSPs are classified according to their molecular weight (kDa) in six main 
families: HSP40, HSP60, HSP70, HSP90, HSP100 and the small HSPs (48-50). In each 
gene family are chaperones that are constitutively expressed, inducible expressed or both 
(50).  
The heat shock factor 1 (HSF1) is the master transcriptional regulator of the HSPs 
gene expression and is activated by heat, inflammation or other stress conditions that 
causes the accumulation of misfolded proteins (51). When HSF1 is activated, by 
phosphorylation, it translocates to the nucleus of the cell and bind to the heat shock 
elements (HSE), which are located in the promoter regions of target genes, enhancing the 
expression of the heat shock genes and, therefore, the expression of the HSPs (7, 50, 51). 
The Hsp27 also known as heat shock protein beta-1 (HspB1) belongs to the family 
of the small heat shock proteins due to their low molecular mass (27kDa). This class I 
small heat shock protein acts through ATP-independent mechanisms and is expressed 
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constitutively and ubiquitously in most of the cells. The Hsp27 is activated through 
phosphorylation by several stress conditions, namely heavy metals, oxidative stress, 
hormones, hypoxia and others (51). This phosphorylation is catalyzed by mitogen-
activated protein kinases associated protein kinases (MAPKAP kinases 2, 3), target of the 
MAP p38 protein kinase (47, 52). Despite their functions as molecular chaperone, Hsp27 is 
also implicated in modulation of cell growth, differentiation, redox state and 
tumorigenicity (53, 54). Increased levels of Hsp27 have been implicated in several 
neurodegenerative disorders and cancers, such as breast and endometrial cancer and 
leukemia (50), and also mutations are associated with Charcot-Marie-Tooth and distal 
hereditary motor neuropathy, both characterized by degeneration of peripheral nerves (48). 
The upregulation of Hsp27 has a role in the protection of the cells against apoptosis by 
tumor necrosis factor-alpha (TNF-α) (53). Thus, this HSP is involved in many cell 
functions, being also involved as a potential therapeutic target for several diseases. 
 
1.6. HeLa Cells 
HeLa cells are the first human cell line established in culture in 1951 from 
Henrietta Lacks, a patient with cervical cancer (55). This cell line name comes from the 
first two letters of the patient’s name (56). HeLa cells have important features that enable 
them to be easily used in laboratory researches. Different from normally somatic cells that 
undergo senescence, losing the ability to replicate themselves after some generations, 
HeLa cells divide indefinitely and are resistant to apoptosis. Thus, they are immortalized 
and easy to culture and maintain (55, 57). Since their discovery, this cell line becomes the 
most widely used for biomedical researches, being used to evaluate the biochemical 
pathways involved in normal and disease tissues of human cells (55, 58).  Initially, HeLa 
cells were used to develop the vaccine against polio virus, a human enterovirus that causes 
poliomyelitis, and since then HeLa cells are used in several areas, from cancer 
investigations to the mapping of genes, treatment of diseases and mechanisms associated 
with apoptosis (58). Indeed this cell line is highly used as a model to study biomedical 
features, being an important tool for biomedical research. 
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1.7. Reporter Systems 
Several biological studies use reporter systems to introduce or select genes of 
interest in order to monitor their functions in cells. For that, fluorescent proteins in 
combination with other proteins of interest form reporter systems (59, 60). These 
fluorescent proteins can serve as probes to monitor characteristics of interest within living 
cells and, associated with proteins of interest can provide important data about protein’s 
distribution, their dynamics and association with other proteins (60). So, fluorescent 
proteins can be easily quantified and reflect the expression of a characteristic of interest by 
enzymatic activity, fluorescence, colorimetric or luminescence intensity (59).  
Green Fluorescent Protein (GFP) was discovered and isolated from Aequorea 
victoria, a bioluminescent jellyfish and is the most used fluorescent protein, exhibiting 
green light when exposed to light in the blue to ultraviolet range (59, 60). GFP folds into a 
β-barrel of eleven strands, with a helix in the middle. Helical segments cover the ends and 
help to isolate the internal chromophore (60, 61). GFP can be separated in two segments 
that fused with two other proteins emit fluorescence. For this protein the folding state is 
essential for fluorescence emission. Thus, denatured GFP is not fluorescent, restoring the 
fluorescence upon renaturation and the chromophore alone is also not fluorescent (61). To 
improve the GFP function, two amino acids were mutated to promote brightness and 
folding and the resulting protein is called eGFP (enhanced GFP) (60). 
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1.8. Aim of the Study  
Several studies report the implications of translation errors and the accumulation of 
misfolded proteins in some diseases. In order to clarify this, the main objective of this 
study was to develop a HeLa stable cell line expressing a reporter system with the fusion of 
the HspB1 (Hsp27) and GFP, to monitor protein misfolding and proteotoxic stress in 
human cells. Therefore, to construct the reporter system, this study had the following 
objectives: 
- Construction of a pcDNA3.1 plasmid with the HspB1-GFP promoter and 
coding sequence; 
- Transfection of the pcDNA3.1 with HspB1-GFP in HeLa cells; 
- Generation of a HeLa stable cell lines expressing the reporter fusion system 
HspB1-GFP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter II –  
Material and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
 
2.1. Experimental Model 
To monitor protein aggregation in cells, an aggregation reporter expressing HspB1-
GFP was developed. HspB1 is a heat shock protein that is recruited in stress situations and 
binds to misfolded proteins, allowing the action of other heat shock proteins, to refold back 
the conformation of the protein (62). GFP is the most useful tool in biological studies 
because has an important function as biosensor to report biological conditions in cellular 
environment (63). Thus, the cellular localization of this HspB1-GFP fusion reporter 
fluorescence to foci can identify situations where protein misfolding is increased.  
To perform this project a HeLa cell line was used. This cell line was first isolated 
from a woman who had an aggressive glandular cervical cancer and since then it became 
an important science instrument implemented in a large amount of researches (56).  
A HeLa cell line was transfected with plasmids: pcDNA3.1 containing the reporter 
fusion system HspB1-GFP, pcDNA3.1 only containing GFP, which is the control in the 
several assays performed. A negative control with HeLa parental cells was also performed 
to monitor the transfection of the plasmids. Cells were grown in a specific medium 
(DMEM supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin-
Streptomycin (Pen-Strep)) and, to validate this reporter system, transfected transient cells 
were incubated after 48 hours with a stressing agent that causes the appearance of stress 
granules, and might be enriched in misfolded proteins, that could be visualized in the 
fluorescence microscope. HeLa cells were transfected with the reporter system and stable 
cell lines were later obtained by Geneticin (G418) selection. G418 resistance gene is 
included in the pcDNA3.1 plasmid, so only the cells that have incorporated the plasmid are 
able to grow in the presence of G418. Stable transfected cells were then incubated with a 
stressing agent at different concentrations to monitor protein misfolding and the 
appearance of stress granules, in order to validate the stable cell lines expressing the 
reporter HspB1-GFP. 
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2.2. Material and Methods 
2.2.1. pCS2 Plasmid 
To create the reporter fusion system HspB1-GFP, GFP was first amplified from the 
pCS2 palsmid. This plasmid contains a promoter region of a cytomegalovirus (IE94), a 
SV40 polyadenylation (PolyA) signal, and an ampicillin resistance gene (Figure 6). A 
Polimerase Chain Reaction (PCR) reaction mix (Annex 1) was made according to the 
number of samples and primers tested (Table II). For that, primers for eGFP were used, 
containing the XhoI and HindIII restriction enzymes, to amplify GFP already with the 
restriction site overhangs so the GFP could be inserted into the pcDNA3.1 plasmid. In 
order to amplify GFP with high-fidelity a pfu DNA polymerase was used, because this 
enzyme has superior thermos-stability than the commonly used, the Taq DNA polymerase. 
PCR was performed in the MyCycler™ Thermal Cycler (Bio-Rad). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. pCS2 plasmid containing GFP coding sequence. 
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Table II. Primers used in PCR reaction and their sequence. 
Primers Sequence 
Forward eGFP XhoI 5' CCGCTCGAGATGGTGAGCAA 3' 
Reverse eGFP HindIII 5' CCCAAGCTTTTACTTGTACAGCT 3' 
 
2.2.2. pcDNA3.1 Plasmid 
Another plasmid was used, the pcDNA3.1 that already had the human HspB1 
promoter and coding region. To clone the GFP amplified from the pCS2 plasmid into the 
pcDNA3.1 vector (Figure 7), were used HindIII and XhoI restriction enzymes that digest 
the plasmid in specific regions, allowing the subsequent ligation of GFP. pcDNA3.1 also 
had the human promoter region, a SV40 promoter and origin, SV40 Poly(A) signal and an 
ampicillin resistance gene that facilitates the selection of Escherichia coli (E. coli) 
competent cells containing the plasmid. Besides ampicillin, G418 is a good marker to 
select monoclonal populations in stable transfected cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. A fluorescence reporter system with the fusion of HspB1 and GFP cloned in pcDNA3.1. 
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2.2.3. Cloning Assay 
A digestion with the XhoI and HindIII restriction enzymes was performed, with 
different reactions, according to the table III. The PCR product that results from 
amplification of GFP from pCS2 plasmid was digested with the restriction enzymes to 
posteriorly be cloned in the pcDNA3.1 plasmid. Also the pcDNA3.1 was digested with the 
same enzymes, both the pcDNA3.1 plasmid and the pcDNA3.1 HspB1. 
 
Table III. Reaction mix of the digestion with the restriction enzymes. 
Reactions Mix 
GFP XhoI and Hind III 
R Buffer (10x) - 2µL 
XhoI - 1µL 
HindIII - 1µL 
DNA - 1µg 
Water up to 20µL 
pcDNA3.1 XhoI and HindIII 
 
pcDNA3.1 HspB1 XhoI and HindIII 
R Buffer (10x) - 2µL 
XhoI - 1µL 
HindIII - 1µL 
DNA - 1µg 
Water up to 20µL 
 
These reactions were incubated with XhoI and HindIII restriction enzymes 
overnight at 37ºC and then treated with FAST AP for 2 hours at 37ºC to avoid the 
recircularization of the plasmid. The next step was to denature these reactions at 80ºC in 
the thermoblock to obtain the DNA products. These DNA products were purified using a 
DNA purification kit (Nzytech), according to the manufacturer’s instructions and DNA 
concentration was quantified using a DeNovix DS-11 spectrophotometer (Frilabo). 
Next, the ligation step between the pcDNA3.1 plasmids (pcDNA3.1 and pcDNA3.1 
HspB1) and the GFP was performed. For that we diluted the plasmid and the insert to a 
concentration of 10ng/µL and 4 different reactions were prepared, one for positive control 
(with the circular plasmid), one for negative control (without the GFP insert) and two to 
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test ligation efficiency with different ratios (1:3, 1:5), for both pcDNA3.1 and pcDNA3.1 
HspB1 (Annex 2). These ligation reactions were left overnight at 16ºC.  
 
2.2.4. Transformation (Escherichia coli (E. coli) DH5α) 
E.coli competent cells were incubated with ligation reactions to incorporate the 
DNA of the pcDNA3.1 plasmid. For that 10µL of the reactions obtained on the previous 
step was added to 200µL of E.coli competent cells and incubated for 30 minutes on ice, 90 
seconds at 42ºC and then left two minutes on ice. 800µL of Super Optimal broth with 
Catabolite repression (SOC) medium was added and then the reactions were incubated at 
37ºC for 1 hour in constant shaking (180 rpm). After that, the reactions were centrifuged 
for 3 minutes at 4000 rpm and plated in Lysogeny Broth (LB) selective medium 
supplemented with ampicillin and incubated overnight at 37ºC. Several vials were made 
with some colonies of transformed E. coli cells cultivated in LB medium supplemented 
with ampicillin, and incubated overnight in constant shaking at 37ºC. These vials were then 
frozen at -80ºC. 
 
2.2.5. DNA Extraction and Quantification 
Nzytech MiniPrep kit was used to extract DNA from the plasmid in transformed E. 
coli cells. Then, DNA concentration was quantified using a DeNovix DS-11 
spectrophotometer (Frilabo).  
 
2.2.6. DNA Sequencing 
To confirm if the GFP sequence was inserted into the pcDNA3.1 plasmid, the 
samples were sequenced by STAB VIDA. According to the YOU TUBE IT sequencing 
service, 3 microtubules with 10µL of the DNA sample at 100ng/µL as well as 3µL of 
10µM of the primer, each were prepared. The reactions were:  
1 – Plasmid (pcDNA3.1 HspB1-GFP) and an HspB1 Forward primer that binds to 
the beginning of the HspB1 sequence (HspB1 Forward: 
5’AGTTGTATGCCCCAACCCAA3’); 
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2 – Plasmid (pcDNA3.1 HspB1-GFP) and an HspB1 Forward primer that binds to 
the middle of the HspB1 sequence (HspB1 Forward middle: 5' 
CGGAAATACACGTGAGTCCT 3'); 
3- Plasmid (pcDNA3.1 HspB1-GFP) and a GFP Forward primer that binds to the 
beginning of the GFP sequence (eGFP Forward: 5' ATGGTGAGCAAGGGCGAGGA 3’). 
The retrieved data was analyzed with BioEdit. A pairwise alignment between two 
sequences, allowing the ends to slide was performed. 
  
2.2.7. Cell Culture 
HeLa cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM), 
supplemented with 10% of FBS and 1% of Pen-Strep.  Cells were kept in an incubator at 
37ºC with 5% CO2 and 95% of humidity.  
For all of the assays cells were detached from the plates with 0,05% trypsin and 
incubated 5 minutes at 37ºC. To neutralize trypsin effect, DMEM was added and then the 
cell suspension was centrifuged at room temperature and ressuspended in medium. Cell 
density was determined using a Neubauer chamber to plate only the desired amount of 
cells (2x105 cells/mL) for the assays performed. 
 
2.2.8. Transfection 
Transfection was performed to deliver DNA from the different pcDNA3.1 plasmids 
into HeLa cells. Cells were plated in 6 multi well plates with a density of 2x105 cells/mL 
and after 24 hours transfection was performed using Lipofectamine® 2000. One hour 
before transfection, the medium was changed for a medium without antibiotics, as 
antibiotics can affect the transfection efficiency. HeLa cells were transfected with both 
pcDNA3.1 GFP and pcDNA3.1 HspB1-GFP, as well as the negative control that only had 
lipofectamine, without the plasmid. 1µg of the plasmid for the DNA complexes and 2µL of 
Lipofectamine® 2000 (ratio 1:2) were used. After 7 hours of incubation the medium was 
changed to a medium with antibiotics and cells were kept in culture for at least 48 hours 
before any other experiment.  
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2.2.9. Stable cell lines  
Cells were transfected with the pcDNA3.1 HspB1-GFP plasmid and 72 hours later 
G418 antibiotic was added to select only the cells containing the plasmid. Then, successive 
dilutions of stable clones were made in a 96 well dishes and only the wells with 1 colony 
were selected. These 1 colony wells grown in the presence of G418 until confluence was 
reached and then replated in a 24 well culture dishes, and later in 6 well culture dishes. 
Once confluence was reached, cells were divided into bigger plates and then part of these 
stable cells was tested to see if they expressed the plasmid. 
 
2.2.10. Stimulation with Sodium Arsenite 
48 hours after transfection cells were incubated with sodium arsenite (NaAsO2) at 
different concentrations (250µM and 500µM). After 30 minutes of incubation cells were 
obtained by trypsinization and pellets from centrifugation were taken to perform the 
several assays. This assay was performed for both transient and stable monoclonal cells 
generated from the transfected cells. 
 
2.2.11. Fixation and Fluorescence Microscopy 
Coated coverslips (Corning™) were placed in 6 well plates to promote cell growing 
and adherence to the coverslip. After 48 hours and the incubation with or without sodium 
arsenite, the culture medium was removed and cells were washed 3 times with phosphate 
buffered saline (PBS). Cells were then fixed with a solution containing 4% of 
paraformaldehyde and 4% of sucrose and incubated 15 minutes at room temperature.  
Enough volume of 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI – 0,5µg/mL) 
was added to cover the coverslip and incubated for 15 minutes at room temperature, 
protected from the light. Coverslips were washed 3 times with PBS and mounted in a glass 
slide with Fluoroshield mount media. Slides were dried in the dark and then examined in 
the Zeiss Axio Imager.Z1 fluorescence microscope. 
 
 31 
 
2.2.12. Polimerase Chain Reaction (PCR) 
After DNA extraction from pellets obtained in step 2.2.10 by NZY Tissue gDNA 
Isolation Kit (Nzytech) and quantification of the DNA concentration, a PCR was 
performed to verify if the right sequence was correctly inserted into HeLa cells. To amplify 
the HspB1-GFP and GFP sequences a concentration of 100ng of DNA and two pairs of 
primers were used, as represented in table IV. A reaction mix was prepared (Annex 3), 
according to the number of the samples tested, and primers were diluted to a concentration 
of 10µM. PCR was then performed in the MyCycler™ Thermal Cycler (Bio-Rad), 
according to the cycle represented in Annex 3. 
 
Table IV. Primers used and their sequence 
Primers Sequence 
eGFP Forward 5' ATGGTGAGCAAGGGCGAGGA 3’ 
eGFP Reverse 5' TTACTTGTACAGCTCGTCCA 3' 
HspB1 Forward Middle 5' CGGAAATACACGTGAGTCCT 3'  
 
2.2.13. Agarose Gel Electrophoresis 
To verify if the PCR products were amplified correctly, according to their 
molecular weight, an electrophoresis on a 2% agarose gel was performed. PCR products 
ran with 6X Loading Dye (Thermo Scientific) in an agarose gel with Green Safe Premium 
(Nzytech) at 80V, in an electrophoretic container with Tris-Acetate-EDTA (TAE) for 
around 30 minutes. Gels were then analyzed in the ChemiDoc™ XRS+ System (Bio-Rad) 
with the Image Lab™ software.  
 
2.2.14. Protein Extraction and Quantification 
To obtain total protein extracts, pellets were resuspended in 100µL of ELB protein 
lysis buffer. This buffer broke cell membranes, allowing the study of their content. Protein 
extracts were then sonicated for 2 cycles during 15 seconds each and centrifuged 20 
minutes at 200g and 4ºC. In the end, supernatants were kept for the next phase of total 
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protein quantification. During all procedures cells should remain in ice, avoiding the 
activity of proteases. 
Quantification of total protein was performed using Pierce™ BCA Protein Assay 
Kit (Thermo Scientific), following the procedures of the manufacturer. After 30 minutes of 
incubation at 37ºC to develop colorimetric reaction, absorbance was measured at 575nm in 
a microplate reader and results were analyzed.  
 
2.2.15. Western Blot 
Western blot is an important technique that allows the identification of specific 
proteins. This technique separates proteins according to their molecular weight through 
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE). Then, these 
proteins are transferred to a solid membrane and incubated with specific primary and 
secondary antibodies to target proteins of interest (64). 
A concentration of 20 µg of total protein was loaded in the 10% polyacrylamide 
gel, according to the quantity measured in the BCA Protein Assay Kit. Samples were 
prepared with 6X SDS Protein Loading Buffer and then denatured at 95ºC for 5 minutes in 
constant shaking. Gel was loaded with a molecular marker (Nzy Colour Protein Marker II) 
in the first well followed by the samples, and then SDS 1X Running Buffer was added to 
the electrophoretic container to immerse the running gel. SDS-PAGE ran for about 2 hours 
at 80V in the first 15 minutes, until samples pass through the stacking (upper part of the 
gel), and then at 100V the rest of the time. Finished the SDS-PAGE, gel proteins were 
transferred to a 0.2µm nitrocellulose membrane in the Trans-Blot® Turbo™ Transfer 
System for 7 minutes and blocked 1 hour at room temperature with Tris-Buffered Saline-
Tween (TBS-T) with 5% of Bovine Serum Albumine (BSA), to avoid unspecific bonds. 
After blocking, membranes were incubated with primary antibody for two hours (anti-
GFP, Clontech, dilution 1:1000) or overnight (anti-HspB1, StressMarq, dilution 1:1000) at 
room temperature or 4ºC, respectively. After removal of primary antibody, membranes 
were washed 3 times with TBS-T, incubating 5 minutes between washes, and then 
incubated with anti-mouse secondary antibody (IRDye 800 Li-CoR Biosciences, dilution 
1:1000) for 1 hour at room temperature, protected from light. Membranes were washed 2 
times with TBS-T, 5 minutes each and 1 with TBS for 5 minutes. 
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Membranes were scanned in an Odyssey Infrared Imaging System (LI-COR, 
Biosciences Inc.) and results were analyzed in the Odyssey software (LI-COR, Biosciences 
inc.). 
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3.1. Plasmid Construction 
3.1.1. Plasmid Amplification 
Two different plasmids were constructed, pcDNA3.1 GFP and pcDNA3.1 HspB1-
GFP, as described in methods section.  After E.coli transformation, the DNA from the 
different clones of the plasmids was extracted and quantified and a PCR to amplify GFP, in 
order to verify if the cloning was successful, was performed. The results are shown in 
Figure 8, revealing the presence of the GFP in all of the E.coli colonies. 
 
 
 
 
 
 
Figure 8. PCR amplification of pcDNA3.1 in transformed E.coli competent cells. Lane 1: Ladder; Lane 2 to 
Lane 9: GFP amplification from clones 1 to 8 of pcDNA3.1 GFP; Lane 10 to Lane 17: GFP amplification 
from clones 1 to 8 of pcDNA3.1 HspB1-GFP, using Forward and Reverse eGFP primers. Lane 18: negative 
control. 
 
3.1.2. Plasmid Sequencing 
The samples were sequenced by STAB VIDA to confirm if the HspB1-GFP fusion 
was correctly inserted into the pcDNA3.1 plasmid. As the sequence program used only 
have the fidelity of 700 bases, 3 reactions were made to sequence the whole HspB1-GFP 
fusion reporter. According to the sequencing results in Supplemental data, the plasmid 
pcDNA3.1 contains the HspB1 and GFP sequences, as the three reactions used can pair 
with the original HspB1-GFP sequence.  
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3.2. Validation of the reporter system in the HeLa cells 
3.2.1. Transfection 
A transient transfection was performed to incorporate the pcDNA3.1 GFP and the 
pcDNA3.1 HspB1-GFP into the HeLa’s genome in 6 well plates, as shown in Figure 9. 
And 48 hours after the cells were stimulated with different concentrations of sodium 
arsenite to induce stress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. HeLa cells transient transfection with pcDNA3.1 GFP and pcDNA3.1 HspB1-GFP. Well 1: HeLa 
parental; Well 2: HeLa transfected with pcDNA3.1 GFP; Well 3: HeLa transfected with pcDNA3.1 HspB1-
GFP; Well 4: HeLa transfected with pcDNA3.1 HspB1-GFP and incubated with sodium arsenite at 250µM; 
Well 5: HeLa transfected with pcDNA3.1 HspB1-GFP and incubated with sodium arsenite at 500µM. 
 
3.2.2. PCR 
To ensure that HeLa transient cells incorporate properly the plasmid, a PCR was 
performed. These results confirm the integration of the pcDNA3.1 plasmid, both 
containing GFP and HspB1-GFP, in HeLa’s genome, through the utilization of two 
different pairs of primers, one for the amplification of GFP (A) and another pair to amplify 
HspB1-GFP (B), as shown in Figure 10. 
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Figure 10. (A) GFP PCR amplification and (B) HspB1-GFP PCR amplification from HeLa cells. Lane 1: 
Ladder; Lane 2: pcDNA3.1 GFP replica 1; Lane 3: pcDNA3.1 HspB1-GFP replica 1; Lane 4: pcDNA3.1 
HspB1-GFP with sodium arsenite at 250µM replica 1; Lane 5: pcDNA3.1 HspB1-GFP with sodium arsenite 
at 500µM replica 1; Lane 6: Negative control replica 2; Lane 7: pcDNA3.1 GFP replica 2; Lane 8: 
pcDNA3.1 HspB1-GFP replica 2; Lane 9: pcDNA3.1 HspB1-GFP with sodium arsenite at 250µM replica 2; 
Lane 10: pcDNA3.1 HspB1-GFP with sodium arsenite at 500µM replica 2. 
 
3.2.3. Fluorescence Microscopy  
HeLa cells were transiently transfected with pcDNA3.1 GFP and pcDNA3.1 
HspB1-GFP. GFP is a fluorescent protein, so 48 hours after transfection the integration of 
the plasmid in HeLa cells can be visualized by fluorescent microscopy. In Figure 11 the 
integration of the pcDNA3.1 HspB1-GFP (A) and the nucleus marked with DAPI (B) are 
shown. In Figure 12 the integration of pcDNA3.1 HspB1-GFP in HeLa cells (A) and the 
nucleus marked with DAPI (B) are shown. These cells in Figure 12 were incubated with 
sodium arsenite at the concentration of 500µM to test the appearance of stress granules in 
cells, as indicated by the arrows. 
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Figure 11. HeLa cells transiently transfected with pcDNA3.1 HspB1-GFP, which is the control, and stained 
with DAPI, to access the cell nucleus. Cells were visualized at the fluorescence microscope with (A) 
fluorescent GFP probe and (B) DAPI (63x). 
 
A  B 
 
Figure 12. HeLa cells transiently transfected with pcDNA3.1 HspB1-GFP, incubated 30 minutes with sodium 
arsenite at 500µM and stained with DAPI, to access the cell nucleus. Cells were visualized at the 
fluorescence microscopy (63x). In (A) were shown the stress granules indicated by the arrows.  
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3.2.4. Western Blot  
To validate the expression of GFP and HspB1 as well as the reporter fusion HspB1-
GFP in HeLa transient cells, the western blot technique was also performed. The relative 
expressions of GFP and HspB1 are presented in Figure 13 (A) and (B), respectively, as 
well as the respective fusion reporter (HspB1-GFP). 
 
A 
     
 
    
 
 
 
B 
  
 
 
 
 
 
 
 
Figure 13. Expression of GFP (A) and HspB1 (B) in HeLa transient cells. Lane 1: HeLa parental cells; Lane 
2: HeLa pcDNA3.1 GFP; Lane 3: HeLa HspB1-GFP; Lane 4: HeLa HspB1-GFP with sodium arsenite at 
250µM; Lane 5: HeLa HspB1-GFP with sodium arsenite at 500µM. Total protein was extracted from HeLa 
cell pellets of the different conditions tested, described in the legend, and then 10% polyacrylamide gel was 
loaded with 20µg of total protein. Proteins were transferred to a nitrocellulose membrane and incubated with 
the respective antibodies.  
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3.3. Monoclonal cell lines  
3.3.1. Monoclonal Cells Selection 
To select only monoclonal strains from HeLa HspB1-GFP stable cells, successive 
dilutions in 96 well plates were made. Cells were visualized under the optical microscope 
to monitor their growing and wells with two or more colonies were despised. When one 
colony wells reach confluence, cells were plated in 24 well plates, and then in 6 well 
plates. After that, those clones were stimulated with different concentrations of sodium 
arsenite. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Representation of a 96 well plate used for selection of monoclonal cells of HeLa HspB1-GFP. 
 
3.3.2. PCR 
After cell selection with G418, to select only the HeLa cells that express the fusion 
plasmid, and the selection of monoclonal cells through successive dilutions, the HspB1-
GFP fusion was amplified from the four successful clones obtained to verify if those lines 
were expressing the desired fusion. The incorporation of pcDNA3.1 HspB1-GFP in the 
stable transfected cells was evaluated by PCR and the results are shown in Figure 15. 
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Figure 15. (A) GFP PCR amplification and (B) HspB1-GFP PCR amplification from monoclonal stable 
HeLa HspB1-GFP cells. Lane 1: Ladder; Lane 2: HeLa HspB1-GFP clone 1; Lane 3: HeLa HspB1-GFP with 
sodium arsenite at 250µM clone 1; Lane 4: HeLa HspB1-GFP with sodium arsenite at 500µM clone 1; Lane 
5: HeLa HspB1-GFP clone 2; Lane 6: HeLa  HspB1-GFP  clone 3; Lane 7: HeLa HspB1-GFP clone 4.  
 
3.3.3. Fluorescence Microscopy  
The integration of the pcDNA3.1 HspB1-GFP plasmid was also evaluated by 
fluorescence microscopy and the selected clones were studied with or without the influence 
of the sodium arsenite. Figure 16 shows one of the stable HeLa cell lines expressing the 
HspB1-GFP control without the action of the sodium arsenite, in A, and with sodium 
arsenite at concentration of 500µM, in B, which is visible cell shrinkage and the 
translocation of HspB1-GFP to foci near the nucleus. Figure 17 shows the HspB1-GFP 
stable cell line control (A) and this stable cell line stimulated with sodium arsenite at 
250µM (B), showing cell shrink and the appearance of stress granules.  
 
 A B 
Figure 16. HeLa HspB1-GFP cell line stained with DAPI (20x). In (A) is shown the HeLa HspB1-GFP 
control and (B) with sodium arsenite at 500µM. White arrows indicate the stress granules.  
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A B  
Figure 17. HeLa HspB1-GFP cell line stained with DAPI (20x). In (A) is shown the HeLa HspB1-GFP 
control and (B) with arsenite at 250µM. White arrows indicate the stress granules.  
 
3.3.4. Western Blot  
To verify the expression of GFP and HspB1 as well as the fusion reporter in stable 
monoclonal HeLa cells, a western blot was performed and their relative expression is 
revealed in Figure 18. In (A) is presented the expression of GFP and the fusion reporter 
HspB1-GFP. In (B) is shown the expression of HspB1 as well as the fusion reporter 
HspB1-GFP. 
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Figure 18. Expression of GFP (A) and HspB1 (B) in stable monoclonal HeLa cells. Lane 1: HeLa parental 
cells; Lane 2: HeLa HspB1-GFP; Lane 3: HeLa HspB1-GFP with sodium arsenite at 250µM; Lane 4: HeLa 
HspB1-GFP with sodium arsenite 500µM. Total protein was extracted from HeLa cell pellets with different 
conditions described in the legend, and then 10% polyacrylamide gel was loaded with 20µg of total protein. 
Proteins were transferred to a nitrocellulose membrane and incubated with the respective antibodies.  
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4.1. Discussion 
The process of translation is very important for the cell as proteins are involved in 
every cellular process, and so, the maintenance of a stable proteome is essential for life. 
However translational errors can occur, leading to mistranslation and protein aggregation, 
which is reported in some diseases and studies (7, 21, 24, 30). Protein misfolding and 
aggregation are mostly the cause to the onset of many neurodegenerative disorders, such as 
Alzheimer’s, Parkinson’s and Huntington’s disease, as well as Amyotrophic Lateral 
Sclerosis (ALS). Thus, monitoring the protein misfolding and aggregation are a great 
strategy to understand the molecular basis of these disorders (65).  
In this study a reporter fusion system expressing HspB1-GFP to monitor 
proteotoxic stress and protein aggregation was developed. This reporter can be used in 
small interfering RNA (siRNA) screenings to identify human tRNA modifying enzymes 
involved in protein homeostasis, or any other molecule that contribute to protein 
aggregation. 
 
 
4.1.1. Plasmid Construction and Sequencing 
In this study, a pcDNA3.1 plasmids expressing both GFP and HspB1-GFP were 
successfully created, as the results of the PCR for plasmid construction show plasmid 
integration and stability in every E.coli colonies, when tested with GFP primers. The 
HspB1 primers were not tested because HspB1 was already integrated in the pcDNA3.1 for 
previous studies and the objective was to see if the GFP was properly integrated in the 
pcDNA3.1 plasmid. The sequencing results corroborate the PCR results, showing proper 
integration and stability of this reporter system in the plasmid. Although in the PCR were 
only used GFP primers, sequencing also with the HspB1 primers proved the integration of 
the whole HspB1-GFP fusion reporter. 
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4.1.2. Validation of the Reporter System 
Fusion proteins are widely used to evaluate the expression of particular features of 
interest, as the expression of the reporter systems reflects the expression of the 
characteristics in study. So the reporter systems can be easily quantified and measured 
(59). In this study a small heat shock protein (HspB1) fused to the GFP, a fluorescence 
protein, was used to monitor protein aggregation in HeLa cells. First the plasmid 
expressing HspB1-GFP was developed; and then the HeLa transfection was performed. To 
verify the fidelity of the transfection, a PCR was performed and to monitor the expression 
of the reporter fusion system, fluorescence microscopy and the western blot analysis were 
also performed.  
The PCR results from transient transfection of HeLa cells with the pcDNA3.1 GFP 
and pcDNA3.1 HspB1-GFP show properly integration of both plasmids. To corroborate 
these results, the HeLa cells were visualized under the fluorescence microscope for protein 
aggregation evaluation, as cells were stimulated with sodium arsenite at concentrations of 
250µM and 500µM. Fluorescence microscopy results showed the appearance of stress 
granules in the HeLa cells transiently transfected with pcDNA3.1 HspB1-GFP and 
stimulated with sodium arsenite at 500µM, when compared to these cells without the 
action of sodium arsenite. The results also revealed the localization of this fusion reporter 
HspB1-GFP to the nucleus of the cell. 
In response to the environmental stimuli, the cells activate mechanisms to prevent 
damage. One of these mechanisms is the formation of stress granules that are aggregates of 
the translation preinitiation complexes. The formation of the stress granules leads to 
inhibition of the translation and the synthesis of HSPs and enzymes for stress response (66, 
67). The HSPs, namely HspB1, have an important role on regulation of the stress response 
and on the maintenance of the cell homeostasis, preventing protein aggregation (68, 69). A 
study in Rat-1 cardiac fibroblast revealed that under normal conditions the HspB1 was 
distributed throughout the cytoplasm of the cells. However, after heat shock stimuli, a large 
proportion of HspB1 was translocated to the nucleus, developing nuclear granules. In the 
same study the investigators transiently expressed the human wild type HspB1 in Rat-1 
cells. After exposing the cells to heat shock, the investigators found a fraction of the 
human HspB1 concentrated in stress granules in the cell nucleus, thus revealing that the 
human HspB1 had the same behavior as the rat homologous (68). 
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 The western blot showing the results for GFP and HspB1 expression were also a 
key to validate this reporter system. For GFP expression in transient cells there were no 
expression of GFP (32kDa) in almost all conditions tested, except for the cells with 
pcDNA3.1 GFP plasmid that showed expression of GFP; and the appearance of band in 
HspB1-GFP conditions (59kDa) proves the expression of the reporter fusion (Figure 13.A). 
Related to the HspB1 expression it was detected in every conditions tested (27kDa) and 
seemed to be stable with the increasing of the sodium arsenite concentration, and the 
59kDa band also proved the expression the HspB1-GFP fusion reporter (Figure 13.B). 
However, an internal control was not used to confirm, quantify and compare these results. 
Some studies refer that HspB1 has a constitutive and ubiquitous expression in most of the 
cell types, playing roles as molecular chaperones in normal cell function. However, some 
stressing agents can increase HspB1 expression, such as oxidative stress, heavy metals, 
hormones, hypoxia and ischemia (51, 70). Some reports also refer that the environmental 
stress, such as treatment with arsenite (71), induces the phosphorylation of the HspB1 at 
three conserved serine residues, namely serine 15, 78 and 82, coinciding with the nuclear 
translocation. This phosphorylation occurs through the MAPKAP kinases 2 and 3, which 
are activated by phosphorylation by MAP p38 protein kinase (52, 62, 68). Moreover the 
state of phosphorylation depends on the type of the stimuli to which the cell is exposed, 
having different roles and biochemical functions and interacting with different substances 
(72).  
 
 
4.1.3.  Monoclonal cell lines 
Stable HeLa cells were transfected with the pcDNA3.1 HspB1-GFP plasmid and 
monoclonal cells were selected from four clones. To evaluate the integration of the plasmid 
and the expression of the reporter a PCR, fluorescence microscopy and Western blot 
techniques were performed. PCR results were consistent with the previous PCR data from 
validation of the reporter system, dictating a good integration of the plasmid in HeLa stable 
cell lines for all of the four clones studied.  
Concerning to the fluorescence microscopy results, there was a difference between 
the cells without sodium arsenite and those stimulated with this stress agent at 
concentrations of 250µM and 500µM. In the HeLa HspB1-GFP is shown cell shrinkage as 
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well as the appearance of the stress granules with sodium arsenite at 500µM when 
compared to the control, where the cells are in normal conditions. With sodium arsenite at 
250µM the stress granules are visible as well as the cell dead and shrinkage, but not with 
the intensity as with the sodium arsenite at the 500µM. A study from Mao and Shelden in 
zebrafish reveals that HspB1 is constitutively expressed and its expression increases in 
response to environmental stimuli and proteotoxic stress (73). Another study in zebrafish 
used a cadmium-induced expression of the Hsp70-GFP reporter gene causing GFP 
fluorescence in several organs and tissues of the zebrafish, as the cadmium concentration 
increases (74).   
The Western blot was consistent to the previous data obtained for reporter system 
validation. There was no expression of GFP; and the appearance of the 59kDa band proves 
the expression of the HspB1-GFP fusion reporter in every conditions except in the HeLa 
parental cells (Figure 18A). The constitutive HspB1 expression was also observed as in 
previous Western blot analysis for transient cells. The HspB1-GFP fusion was also shown, 
except for the HeLa parental cells that do not contain the plasmid (Figure 18.B). However, 
was not used an internal control, as tubulin, to confirm and compare the results of the 
control cells and those stimulated with different concentrations of the sodium arsenite.  
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4.2. Conclusion and Future Perspectives 
In this study, an aggregation reporter system expressing the fusion of the HspB1-
GFP was successfully developed and transfected in stable HeLa cells. The results proved 
that this fusion reporter was correctly transfected in HeLa cells and can be a good model to 
monitor protein aggregation in stress-induced cells, as it can see in fluorescent microscopy 
by the appearance of granules. 
This reporter will be used to monitor protein aggregation in these cells, and to 
further identify the human tRNA modifying enzymes involved in protein homeostasis 
through siRNA screening.  
As HeLa cells express HspB1 constitutively, it should be used another antibody to 
monitor other forms of HspB1, such as the phosphorylated form, because there are some 
evidences that this small heat shock protein is phosphorylated in response to extracellular 
stimuli (75, 76). So, with an antibody for phosphorylated HspB1, the differences between 
the normal and stress conditions should be more accentuated. Also an internal control, such 
as the β-tubulin, should be used to measure the expression of the HspB1 and GFP and to 
compare the expressions of the different concentrations of the sodium arsenite with the 
control. 
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Appendix  
Annex 1 – Reaction mix and cycle used for the amplification of GFP from 
pCS2 plasmid. 
 
Reaction Mix (for 1 reaction) 
Water  37µL 
10X pfu Buffer with Magnesium Sulfate (MgSO4) 5µL 
dNTP mix (10µM) 1µL 
Reverse primer (10µM) 1,25µL 
Forward primer (10µM) 1,25µL 
DNA (100ng) 1µL 
Pfu 1µL 
PCR Cycle  
Initial denaturation – 95ºC, 4 minutes 
Denaturation – 95ºC, 1 minute 
Annealing – 61ºC, 30 seconds 
Extension – 72ºC, 4 minutes 
Final extension – 72ºC, 10 minutes 
 
 
Annex 2 – Ligation reactions. 
 
Reagents Negative Control (1:0) 1:3 1:5 Positive Control 
T4 DNA ligase 10x 
buffer 
2µL 2µL 2µL 2µL 
T4 DNA ligase 1µL 1µL 1µL 1µL 
Plasmid (pcDNA3.1) 1µL 1µL 1µL 1µL 
Insert (GFP) - 3µL 5µL 0µL 
Water 16µL 13µL 11µL 16µL 
 
  
 
35 cycles 
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Annex 3 – Reaction mix and cycle used for the amplification of HspB1-GFP 
and GFP from HeLa cells. 
 
Reaction Mix (for 1 reaction) 
Water up to 50µL 40,25µL 
Dream Taq Buffer 5µL 
dNTP mix (10µM) 1µL 
Reverse primer (10µM) 1,25µL 
Forward primer (10µM) 1,25µL 
DNA (100ng) 1µL 
Taq 0,25µL 
PCR Cycle  
Initial denaturation – 95ºC, 2 minutes 
Denaturation – 95ºC, 30 seconds 
Annealing – 55ºC, 30 seconds 
Extension – 72ºC, 1 minute 
Final extension – 72ºC, 10 minutes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 cycles 
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Solutions 
 
PBS (1L) 
Reagents Quantities  
NaCl 8g 
KCl 0.2g 
Na2HPO4
 1.44g 
KH2PO4 0.24g 
Add H2O to 1L and adjust pH to 7.4 
 
 
Protein Lysis Buffer for Western Blot 
Reagents Quantities  
Triton X-100 50µL 
HEPES 500µL 
NaCl 5M 500µL 
H2O 8.95mL 
ELB - 10mL 
 
Reagents Quantities  
ELB 4,645mL 
DTT (1M) 5µL 
Naf (1M) 5µL 
EDTA 20µL 
EGTA 20µL 
Na3VO4 50µL 
5 Aliquots of 955µL 
On the moment of use add 25L of PMSF 
(100mM) and 20µL of cOmplete™ EDTA-free 
Protease Inhibitor Cocktail tablets to each 
aliquot. 
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Two Resolving gels for Western Blot (10%) 
Reagents Quantities  
distilled H2O 3.6mL 
Tris HCl 1,5M 
pH8.8 
3.75mL 
40% Acrilamide 
29:1 
2.5mL 
10% SDS 100µL 
10% APS 100µL 
TEMED 10µL 
 
 
Two Stacking gels for Western Blot (4%) 
Reagents Quantities  
distilled H2O 3.646mL 
Tris HCl 0.625M 
pH6.8 
1mL 
40% Acrilamide 
29:1 
0.5mL 
10% SDS 50µL 
10% APS 50µL 
TEMED 10µL 
 
 
10X Running Buffer for SDS-PAGE 
Reagents Quantities  
Tris 30.2g 
Glycine 144g 
SDS 10g 
Dissolve in 1L of H2O 
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TBS 10X 
Reagents Quantities  
Tris 30g 
NaCl 80g 
KCl 2g 
Add 1L of H2O and adjust pH to 7.6 
 
Tris-Acetate-EDTA (TAE) Buffer (50X) 
Reagents Quantities  
Tris 40mM 
EDTA 2mM 
Acetic Acid 20mM 
Adjust pH to 8.5 and dilute with MiliQ H2O 
 
 
Supplemental Data – Sequencing Results 
 
The sequencing results are supplemental files that were sent together with the thesis 
and open with the BioEdit program. 
 
1. Alignment of the plasmid with the HspB1 Forward primer: 
Alignment pcDNA3.1 HspB1GFP HspB1_Fw.gb  
 
2. Alignment of the plasmid with the HspB1 Forward Middle primer: 
Alignment pcDNA3.1 HspB1GFP HspB1_middle.gb  
 
3. Alignment of the plasmid with the GFP Forward primer:  
Alignment GFP_Fw.gb  
